Drugs & Targets FDA approves Vyloy+chemo for gastric or GEJ junction adenocarcinoma with CLDN18.2-positive tumors October 25, 2024Vol.50 No.40
Drugs & Targets FDA accepts NDA, grants priority review for Pixclara glioma imaging agent October 25, 2024Vol.50 No.40
Drugs & Targets Jaguar Health launches FDA-approved treatment for “chemo mouth” October 18, 2024Vol.50 No.39
Drugs & Targets FDA approves inavolisib + palbociclib + fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer October 11, 2024Vol.50 No.38
Drugs & Targets FDA clears the way for multi-center investigator-initiated study of Alpha DaRT in immunocompromised patients with recurrent cSCC October 11, 2024Vol.50 No.38
Drugs & Targets FDA grants clearance for radiation oncology tool to calculate absorbed dose of radionuclides October 11, 2024Vol.50 No.38
Drugs & Targets FDA approves neoadjuvant/adjuvant Opdivo for resectable NSCLC October 04, 2024Vol.50 No.37
Drugs & Targets FDA approves Retevmo for medullary thyroid cancer with RET mutation October 04, 2024Vol.50 No.37
Drugs & Targets FDA approves Cologuard Plus Test for non-invasive CRC screening October 04, 2024Vol.50 No.37
Drugs & Targets FDA approves Sarclisa + VRd for MM not eligible for transplant September 27, 2024Vol.50 No.36
